National Emphysema Treatment Trial

National Emphysema Treatment Trial was a landmark randomized controlled trial conducted in the United States to evaluate the efficacy and safety of lung volume reduction surgery for patients with severe emphysema. Sponsored by the National Heart, Lung, and Blood Institute and the Centers for Medicare & Medicaid Services, it was the largest and most definitive study of its kind. The trial's findings fundamentally reshaped the clinical management of advanced chronic obstructive pulmonary disease and patient selection for surgical intervention.

Background and Rationale

By the late 20th century, emphysema, a major component of chronic obstructive pulmonary disease, was a leading cause of morbidity and mortality, with limited treatment options beyond oxygen therapy and pulmonary rehabilitation. Lung volume reduction surgery, a procedure to remove diseased portions of the lung to improve function, showed promise in uncontrolled studies but was controversial due to high perioperative mortality reported in some centers, notably in a 1996 report from *The Lancet*. This controversy led the Health Care Financing Administration (now Centers for Medicare & Medicaid Services) to issue a non-coverage decision, prompting the need for a rigorous, multicenter trial. The collaboration between the National Heart, Lung, and Blood Institute and Centers for Medicare & Medicaid Services was unprecedented, aiming to provide definitive evidence on the risks and benefits of the surgery compared to maximal medical therapy.

Study Design and Methods

The trial was a prospective, randomized, multicenter study involving 1,218 patients across 17 clinical centers, including institutions like the Cleveland Clinic and University of Pennsylvania. Participants had severe, bilateral emphysema and were randomly assigned to receive either lung volume reduction surgery plus rigorous medical therapy or medical therapy alone. Medical therapy included smoking cessation, pulmonary rehabilitation, bronchodilator medications, and corticosteroids. The primary outcome measures were overall mortality and maximum exercise capacity, as measured by cycle ergometry, assessed over a follow-up period of up to five years. Extensive preoperative testing, including computed tomography and perfusion scanning, was used to characterize disease heterogeneity.

Key Findings and Results

The primary results, published in the New England Journal of Medicine in 2003, demonstrated that the overall trial population did not show a significant survival benefit from surgery. However, prespecified subgroup analyses revealed critical differential outcomes. Patients with predominantly upper-lobe emphysema and low baseline exercise capacity experienced significantly improved survival, exercise capacity, and quality of life. Conversely, patients with non-upper-lobe emphysema and high baseline exercise capacity had higher mortality risk with surgery. The overall 90-day postoperative mortality rate was 7.9%, but varied significantly between patient subgroups. The trial also provided extensive data on pulmonary function test changes, oxygen requirements, and rates of rehospitalization.

Impact and Clinical Implications

The findings had an immediate and profound impact on clinical practice and health policy. Based on the evidence, Centers for Medicare & Medicaid Services revised its national coverage decision to reimburse lung volume reduction surgery but only for the subset of patients meeting the trial's criteria for benefit. This established a new standard of care, emphasizing precise patient selection using computed tomography and cardiopulmonary exercise testing. The trial's data directly informed subsequent clinical guidelines from organizations like the Global Initiative for Chronic Obstructive Lung Disease. Furthermore, it stimulated research into less invasive techniques, paving the way for the development of endobronchial valve procedures and other bronchoscopic lung volume reduction technologies.

Criticisms and Limitations

Criticisms of the trial included its high surgical mortality rate in certain subgroups, which some argued reflected the learning curve of participating surgeons rather than the inherent risk of the procedure in expert hands. The extensive preoperative screening and rigorous medical therapy in the trial setting were also noted to be more intensive than typical community practice, potentially limiting the generalizability of the results. Some researchers questioned the cost-effectiveness of the intervention given the substantial upfront costs and the defined, narrow beneficiary population. Additionally, the rapid evolution of interventional pulmonology techniques after the trial's completion led to debates about whether its conclusions remained fully applicable in the era of bronchoscopic interventions.

Category:Clinical trials Category:Medical research in the United States Category:Pulmonology